今年，细胞出版社中国科学家与 Cell Press 活动迎来了第十年。在过去的 2024 年里，中国科研工作者在 Cell Press 旗下的生命科学、医学、物质科学、交叉科学、可持续发展等领域的期刊发表的原创研究型论文超过 2400 ...

Design We performed single-cell RNA sequencing on 24 patients with GC and spatial transcriptomic profiling on formalin-fixed paraffin-embedded tissue sections from patients and controls. Integrating ...

TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US ...

Cluster 4/5 was treated with the dual ICI regimen of ipilimumab plus nivolumab. This arm remains open to accrual. Clusters 3, 6, and 7 were excluded from the study. Additional secondary endpoints are ...

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key ...

今日与大家汇报原发性纤毛运动障碍（PCD）的进展，我认为对我们未来的工作有所帮助和启发。一、PCD的定义及诊断流程首先看PCD的定义，它强调以支气管扩张为主的呼吸道表现。它是因为先天性的纤毛结构或功能异常，或者多运动纤毛生成减少，导致的呼吸道黏液清除 ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting ...